Stock COLL COLLEGIUM PHARMACEUTICAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Collegium Pharmaceutical, Inc.

Equities

COLL

US19459J1043

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
33.19 USD +5.84% Intraday chart for Collegium Pharmaceutical, Inc. +0.15% +7.83%
Jun. 07 Jefferies Upgrades Collegium Pharmaceutical to Buy From Hold, Adjusts Price Target to $44 From $41 MT
Jun. 05 Collegium Pharmaceutical Insider Sold Shares Worth $814,180, According to a Recent SEC Filing MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 690 692.7 650 778.9 1,004 1,086 - -
Enterprise Value (EV) 1 531.5 775.7 650 778.9 1,004 1,232 891.9 1,086
P/E ratio -30.3 x 26.4 x 10 x -31.4 x 23.9 x 10.7 x 8.49 x 6.82 x
Yield - - - - - - - -
Capitalization / Revenue 2.33 x 2.23 x 2.35 x 1.68 x 1.77 x 1.86 x 1.82 x 1.89 x
EV / Revenue 1.79 x 2.5 x 2.35 x 1.68 x 1.77 x 2.11 x 1.49 x 1.89 x
EV / EBITDA 70.6 x 5.55 x 5.49 x 2.93 x 2.74 x 3.19 x 2.28 x 2.89 x
EV / FCF 24.9 x - - - 3.66 x 3.51 x 2.8 x 3.8 x
FCF Yield 4.02% - - - 27.3% 28.5% 35.8% 26.3%
Price to Book - - - - - 5.1 x 3.03 x -
Nbr of stocks (in thousands) 33,527 34,582 34,797 33,572 32,611 32,715 - -
Reference price 2 20.58 20.03 18.68 23.20 30.78 33.19 33.19 33.19
Announcement Date 2/27/20 2/25/21 2/24/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 296.7 310 276.9 463.9 566.8 583.3 597.5 574.5
EBITDA 1 7.532 139.7 118.3 266 367 386 391.9 376.3
EBIT 1 -23.75 56.23 17.63 33.32 167 211.9 230.7 232
Operating Margin -8% 18.14% 6.37% 7.18% 29.46% 36.33% 38.6% 40.38%
Earnings before Tax (EBT) 1 -22.72 27.58 -3.374 -28.85 75.73 165.9 208.4 233.8
Net income 1 -22.72 26.75 71.52 -25 48.16 124.7 153.5 187
Net margin -7.66% 8.63% 25.83% -5.39% 8.5% 21.37% 25.69% 32.56%
EPS 2 -0.6800 0.7600 1.860 -0.7400 1.290 3.097 3.908 4.870
Free Cash Flow 1 21.34 - - - 274.3 351 318.9 285.8
FCF margin 7.19% - - - 48.4% 60.18% 53.37% 49.75%
FCF Conversion (EBITDA) 283.39% - - - 74.74% 90.94% 81.38% 75.95%
FCF Conversion (Net income) - - - - 569.59% 281.57% 207.72% 152.81%
Dividend per Share - - - - - - - -
Announcement Date 2/27/20 2/25/21 2/24/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 27.36 83.75 123.5 127 129.6 144.8 135.5 136.7 149.7 144.9 142.7 144.9 150.6 148.6 144.9
EBITDA 1 -4.478 43.53 71.18 74.87 76.44 87.62 85.81 89.39 104.2 92.38 92.19 95.08 101.3 97 98.59
EBIT 1 -34.12 -10.02 11.11 20.47 11.76 24.63 35.63 45.01 61.69 49.47 50.16 53.76 59.73 53.4 54.81
Operating Margin -124.71% -11.96% 8.99% 16.11% 9.07% 17.01% 26.29% 32.93% 41.2% 34.14% 35.15% 37.11% 39.67% 35.93% 37.83%
Earnings before Tax (EBT) 1 -38.88 -15.84 -6.646 1.432 -7.791 -17.56 17.8 28.78 46.71 36.62 36.1 43.85 51.24 45.93 48.03
Net income 1 -25.03 -13.07 -5.191 0.457 -7.199 -17.43 13.01 20.63 31.94 27.71 26 31.8 38.54 33.07 34.58
Net margin -91.49% -15.6% -4.2% 0.36% -5.55% -12.04% 9.6% 15.09% 21.33% 19.12% 18.22% 21.95% 25.59% 22.25% 23.87%
EPS 2 -0.7300 -0.3900 -0.1500 0.0100 -0.2200 -0.5100 0.3400 0.6100 0.8200 0.7100 0.6550 0.8050 0.9725 0.8600 0.8900
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 2/24/22 5/10/22 8/4/22 11/3/22 2/23/23 5/4/23 8/3/23 11/7/23 2/22/24 5/9/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 83 - - - 146 - -
Net Cash position 1 159 - - - - - 194 -
Leverage (Debt/EBITDA) - 0.594 x - - - 0.3795 x - -
Free Cash Flow 1 21.3 - - - 274 351 319 286
ROE (net income / shareholders' equity) - - - - - 45.8% 30.9% -
ROA (Net income/ Total Assets) - - - - - 12% 12.6% -
Assets 1 - - - - - 1,039 1,218 -
Book Value Per Share 2 - - - - - 6.510 11.00 -
Cash Flow per Share - - - - - - - -
Capex 1 6.44 5.55 1.94 1.62 0.46 1.64 1.64 1
Capex / Sales 2.17% 1.79% 0.7% 0.35% 0.08% 0.28% 0.27% 0.17%
Announcement Date 2/27/20 2/25/21 2/24/22 2/23/23 2/22/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Collegium Pharmaceutical, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
33.19 USD
Average target price
41 USD
Spread / Average Target
+23.53%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
COLLEGIUM PHARMACEUTICAL, INC. Stock Collegium Pharmaceutical, Inc.
+7.83% 1.09B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+45.82% 765B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.95% 632B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.16% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.86% 331B
ABBVIE INC. Stock AbbVie Inc.
+9.32% 299B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.45% 248B
NOVARTIS AG Stock Novartis AG
+11.88% 216B
ROCHE HOLDING AG Stock Roche Holding AG
-0.78% 219B
AMGEN INC. Stock Amgen Inc.
+5.90% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. COLL Stock
  4. Financials Collegium Pharmaceutical, Inc.